MERRIMACK PHARMACEUTICALS INC false 0001274792 0001274792 2021-06-10 2021-06-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2021 (June 10, 2021)

 

 

Merrimack Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-35409   04-3210530
(State or Other Jurisdiction
of Incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

One Broadway, 14th Floor
Cambridge, MA 02142
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (617) 441-1000

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common stock, $0.01 par value   MACK   Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2021 Annual Meeting of Stockholders of Merrimack Pharmaceuticals, Inc. (the “Company”) held exclusively through a virtual format on June 10, 2021, the Company’s stockholders voted as follows:

1. The stockholders elected the nominees listed below to the Company’s board of directors (the “Board”), each for a one year term ending at the Company’s 2021 annual meeting of stockholders.

 

Nominees

   For      Against      Abstain      Broker Non-Votes  

Gary L. Crocker

     5,660,685        993,233        12,516        2,545,677  

Eric D. Andersen

     5,652,662        1,000,200        13,572        2,545,677  

Noah G. Levy

     5,608,690        994,152        63,592        2,545,677  

Ulrik B. Nielsen, Ph.D.

     5,356,445        1,246,257        63,732        2,545,677  

Russell T. Ray

     5,634,287        967,925        64,222        2,545,677  

2. The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.

 

     Votes  

For:

     5,522,300  

Against:

     1,110,176  

Abstain:

     33,958  

Broker Non-Votes

     2,545,677  

3. The stockholders approved, on a non-binding advisory basis, the one-year frequency of “say-on-pay” votes.

 

Frequency

   Votes  

1 year:

     6,113,951  

2 year:

     27,083  

3 year:

     517,418  

Abstain

     7,982  

Broker Non-Votes

     2,545,677  


4.The stockholders ratified the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.

 

     Votes  

For:

     9,184,891  

Against:

     22,419  

Abstain:

     4,801  

5. The stockholders approved the adoption of the Company’s 2021 Incentive Award Plan as set forth on Annex A in the Company’s Definitive Proxy Statement for the 2021 Annual Meeting of Stockholders.

 

     Votes  

For:

     5,428,711  

Against:

     1,219,106  

Abstain:

     18,617  

Broker Non-Votes

     2,545,677  


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

                                     MERRIMACK PHARMACEUTICALS, INC.
Date: June 14, 2021     By:  

  /s/ Gary L. Crocker

        Gary L. Crocker
        President
Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Merrimack Pharmaceuticals Charts.
Merrimack Pharmaceuticals (NASDAQ:MACK)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Merrimack Pharmaceuticals Charts.